QPS NEUROPHARMACOLOGY

Preclinical CRO for

Get in touchService navigator

QPS Neuropharmacology is the division of QPS that focuses on preclinical studies in CNS diseases, Orphan Diseases and Mental Disorders. The on-site availability of highly predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes makes QPS Neuropharmacology the first choice for most CNS drug development needs.

Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Niemann-Pick Disease, Autism Spectrum Disorder (ASD), Schizophrenia, Lewy Body Dementia (LBD) and other neurodegenerative diseases.

QPS is a global contract research organization (CRO) providing discovery, preclinical and clinical drug development services since 1995. Our mission is to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services. An award-winning leader in the CRO industry, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities.

QPS Neuropharmacology is a preclinical full-service contract research organization (CRO) focusing on CNS diseases, Orphan diseases and mental disorders.

The availability of highly predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes makes QPS the first choice for most needs in CNS drug development.

Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Huntington’s Disease (HD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Niemann-Pick Disease, Autism Spectrum Disorder (ASD), Schizophrenia, Lewy Body Dementia (LBD) and other neurodegenerative diseases.

Why choose us?

Customer satisfaction is our absolute priority

Your timeline is our timeline

f

Every study is custom-built

p

Scientific input to study design and data interpretation

Extensive experience with virtually all drug targets and treatment types

0

Wide range of validated models and techniques for comprehensive compound tests from a single source

AAALAC certification ensures highest quality standards

QPS Austria AAALAC accrediation Logo

QPS NEURO NEWS

January 2020 - Neuroinflammation in the Gaucher disease mouse model 4L/PS-NA

 

Neuroinflammation is a growing field of research in the fight against neurodegenerative diseases and other disorders affecting the central nervous system. We have already shown that 4L/PS-NA mice exhibit strong inflammation in visceral organs and cortical brain regions (Schiffer et al., 2020). Since the cerebellum of 4L/PS-NA mice presents with a highly disturbed morphology (Schiffer et al., 2020), we now evaluated neuroinflammation in this brain region. Our results show that astrocytosis and microgliosis are strongly increased in the cerebellum of 18 week old 4L/PS-NA when labeled with GFAP and IBA1 antibodies, respectively.

Figure 1. Quantification of astrocytosis and activated microglia in the cerebellum of 4L/PS-NA mice. The cerebellum of 4L/PS-NA mice was analyzed for astrocytosis (GFAP; A) and activated microglia (IBA1; B) immunoreactive area (IR) in percent at the age of 18 weeks compared to control littermates. Unpaired T-test. n = 5 per group. Mean + SEM. ***p<0.001. C: Representative images of GFAP, IBA1 and DAPI labeling of the cerebellum in 18 week old 4L/PS-NA and control mice.

 


 

Meet us at the WORLDSymposium in Orlando, Florida, USA

The QPS Neuropharmacology team will attend the WORLDSymposium 2020 and are pleased to meet you at our booth # 413.

Additionally, Vera Niederkofler, PhD will be presenting our newest research results in an oral presentation and a poster:

Oral presentation on 11th of February, 09:00 am

“Neuroinflammation in mouse models of two different lysosomal diseases“

Vera Niederkofler, Ewald Auer, Victoria Schiffer, Magdalena Temmel, Joerg Neddens, Birgit Hutter-Paier

Poster presentation on 11th of February, 04:30-06:30 pm

#292: “Neuroinflammation in mouse models of two different lysosomal diseases“

Vera Niederkofler, Ewald Auer, Victoria Schiffer, Magdalena Temmel, Joerg Neddens, Birgit Hutter-Paier

 

Join us February 10-13 at the Hyatt Regency Orlando, 9801 International Drive Orlando, Florida, USA

In Vitro Services

QPS Austria’s Neuropharmacology Department provides research services with numerous standardized cell culture systems including transgenic and non-transgenic cell lines, glial cells, primary chicken and rat peripheral and central nervous system neurons of different developmental stages and organotypic brain slices. New models are developed and validated on request.

In Vivo Services

We have more than 15 years experience in generating, characterizing and maintaining transgenic disease models and using them for drug testing projects. Several customized behavioral tests, including motor, cognitive, and emotional assays, are offered to phenotype mouse and rat models and to evaluate effects of compounds in different in vivo models.

Ex Vivo Services

Our ex vivo services cover a full range of histological services, a biobank composed of various specimen derived from our in-house in vivo and in vitro models, and numerous well established tests for biomarkers. We are happy to test new protocols and establish new markers to meet your specific needs.

Facebook
Twitter
LinkedIn